Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 6, 2018
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary studyFederica Bruno, Dario Baratti, Antonia Martinetti, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|October 21, 2016
Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complicationEmiliano Tognoli, Matteo Luigi Giuseppe Leoni, Daniele Morelli, et al.
Tumori|January 31, 2007
Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumorsLeonardo Ferrari, Silvia Della Torre, Paola Collini, et al.
Tumori|February 12, 2004
Diagnostic procedures in the follow-up of patients affected by MEN type 2Ettore Seregni, Federica Pallotti, Franco Mattavelli, et al.
International Journal of Food Sciences and Nutrition|September 3, 2013
Effect of 10-day broccoli consumption on inflammatory status of young healthy smokersPatrizia Riso, Stefano Vendrame, Cristian Del Bo', et al.
Oncology|April 18, 2008
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinomaGiuseppe Procopio, Elena Verzoni, Arpine Gevorgyan, et al.
The International Journal of Biological Markers|September 10, 2015
Did circulating tumor cells tell us all they could? The missed circulating tumor cell message in breast cancerEmanuela Fina, Carolina Reduzzi, Rosita Motta, et al.
International Journal of Oncology|April 10, 2003
Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?Leonardo Ferrari, Emilio Bajetta, Antonia Martinetti, et al.
Cancer|March 20, 2002
A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinomaEmilio Bajetta, Giuseppe Procopio, Leonardo Ferrari, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 9, 2004
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patientsNicoletta Zilembo, Emilio Bajetta, Ettore Bichisao, et al.
Pageof 7